124 related articles for article (PubMed ID: 11968077)
1. Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment.
Wikell C; Eap CB; Josefsson M; Apelqvist G; Ahlner J; Baumann P; Bengtsson F
Chirality; 2002 May; 14(4):347-50. PubMed ID: 11968077
[TBL] [Abstract][Full Text] [Related]
2. Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin.
Kugelberg FC; Apelqvist G; Carlsson B; Ahlner J; Bengtsson F
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):80-8. PubMed ID: 16867175
[TBL] [Abstract][Full Text] [Related]
3. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
[TBL] [Abstract][Full Text] [Related]
4. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine.
Wang CP; Howell SR; Scatina J; Sisenwine SF
Chirality; 1992; 4(2):84-90. PubMed ID: 1616828
[TBL] [Abstract][Full Text] [Related]
5. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.
Wikell C; Bergqvist PB; Hjorth S; Apelqvist G; Björk H; Bengtsson F
Clin Neuropharmacol; 1998; 21(5):296-306. PubMed ID: 9789710
[TBL] [Abstract][Full Text] [Related]
6. Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy.
Wikell C; Kugelberg FC; Hjorth S; Apelqvist G; Bengtsson F
Clin Neuropharmacol; 2001; 24(6):324-33. PubMed ID: 11801807
[TBL] [Abstract][Full Text] [Related]
7. Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.
Wikell C; Apelqvist G; Hjorth S; Kullingsjö J; Bergqvist PB; Bengtsson F
Eur Neuropsychopharmacol; 2002 Aug; 12(4):327-36. PubMed ID: 12126872
[TBL] [Abstract][Full Text] [Related]
8. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
[TBL] [Abstract][Full Text] [Related]
9. Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges.
Apelqvist G; Wikell C; Hindfelt B; Bergqvist PB; Andersson G; Bengtsson F
Psychopharmacology (Berl); 1999 Apr; 143(4):408-16. PubMed ID: 10367559
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat.
Strolin Benedetti M; Frigerio E; Tocchetti P; Brianceschi G; Castelli MG; Pellizzoni C; Dostert P
Chirality; 1995; 7(4):285-9. PubMed ID: 7640172
[TBL] [Abstract][Full Text] [Related]
11. Reversal of behavioral changes in rats subjected to portacaval shunt with oral neomycin therapy.
Conjeevaram HS; Nagle A; Katz A; Kaminsky-Russ K; McCullough AJ; Mullen KD
Hepatology; 1994 May; 19(5):1245-50. PubMed ID: 8175148
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat.
Therrien G; Rose C; Butterworth J; Butterworth RF
Hepatology; 1997 Mar; 25(3):551-6. PubMed ID: 9049197
[TBL] [Abstract][Full Text] [Related]
13. [Venlafaxine-containing prolonged release: critical exchange?].
Saussele T
Med Monatsschr Pharm; 2009 Jul; 32(7):239. PubMed ID: 19731750
[No Abstract] [Full Text] [Related]
14. Establishing bioequivalence of racemic venlafaxine formulations using stereoselective assay method: Is it necessary?
Kandhwal K; Dey S; Nazarudheen S; Reyar S; Mishra S; Thudi NR; Khuroo AH; Monif T
Chirality; 2011 Nov; 23(10):948-54. PubMed ID: 21953854
[TBL] [Abstract][Full Text] [Related]
15. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure: role of nitric oxide synthase isoforms.
Chu CJ; Chang CC; Wang TF; Lee FY; Chang FY; Chen YC; Chan CC; Huang HC; Wang SS; Lee SD
J Gastroenterol Hepatol; 2006 Jul; 21(7):1194-9. PubMed ID: 16824075
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters.
Gould GG; Altamirano AV; Javors MA; Frazer A
Biol Psychiatry; 2006 Mar; 59(5):408-14. PubMed ID: 16140280
[TBL] [Abstract][Full Text] [Related]
17. Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.
Apelqvist G; Wikell C; Carlsson B; Hjorth S; Bergqvist PB; Ahlner J; Bengtsson F
Clin Neuropharmacol; 2000; 23(6):304-17. PubMed ID: 11575864
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation.
Haque S; Md S; Fazil M; Kumar M; Sahni JK; Ali J; Baboota S
Carbohydr Polym; 2012 Jun; 89(1):72-9. PubMed ID: 24750606
[TBL] [Abstract][Full Text] [Related]
19. Open-field behavioural alterations in liver-impaired and sham-operated rats after acute exposure to the antidepressant venlafaxine.
Kugelberg FC; Apelqvist G; Wikell C; Bengtsson F
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):155-61. PubMed ID: 16128909
[TBL] [Abstract][Full Text] [Related]
20. Effects of extract of Ginkgo biloba with venlafaxine on brain injury in a rat model of depression.
Qin XS; Jin KH; Ding BK; Xie SF; Ma H
Chin Med J (Engl); 2005 Mar; 118(5):391-7. PubMed ID: 15780208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
